Bristol Myers Squibb's valuation metrics show the stock is a bona fide bargain. However, valuation metrics can be misleading ...
Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data ...
The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing from a $300 ...
Saqib Islam, chief executive Officer of newly launched Beeline Medicines. The pace of private financing in biopharma steps up ...
Bristol Myers Squibb is proving its worth as an M&A competitor, coming out on top not once but twice in terms of fresh acquisitions. Most recently, the pharma’s $4.1 billion bid for ...
Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for approximately ...
After years serving as a rumored target of Big Pharma M&A, Mirati Therapeutics has finally made its sale a reality. The buyer, Bristol Myers Squibb, will pay up to $5.8 billion for the ...
After several years of turning out solid growth, Bristol Myers Squibb knows it’s nearing a patent cliff that’ll wreak havoc later this decade. Still, the company believes a “diversified” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results